Xbrane Gets Action Date As Ranibizumab Filing Accepted By FDA

Gains BsUFA Goal Date Of 21 April 2024 For Biosimilar Rival To Lucentis

 
• By David Wallace
  
Desk calendar showing April 2024
Xbrane has a goal date in April 2024 for its ranibizumab biosimilar • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products